In this review:
- CAPItello-290: capivasertib + paclitaxel in metastatic TNBC
- pCR & OS after neoadjuvant chemotherapy in stage I TNBC
- NATALEE: ribociclib + NSAI in younger patients with HR+/HER2− early breast cancer
- HERA: OFS in HR+/HER2+ breast cancer
- DESTINYBreast-12: T-DXd in HER2+ breast cancer ± brain metastases
- Capecitabine vs. IV chemotherapy for ER+/HER2- breast cancer after progression on endocrine treatment
- POSITIVE: breastfeeding after interruption of endocrine therapy for pregnancy
- Breastfeeding after breast cancer in BRCA carriers
- KEYNOTE-522: final OS results
- PROMENADE: KEYNOTE-522 regimen in ER-low/HER- breast cancer
- T-DXd-related ILD in HER2-driven breast cancer
Please login below to download this issue (PDF)